Sapho Bio Secures $5M, Advances Rapid Sterility Testing Through USP<1223> ValidationSAN CARLOS, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sapho Bio, a biotechnology company developing a rapid microbiology release platform for precision medicine, announces $5M in secured funding, USP<1223> Validation, and validated rapid sterility test results. Together, these milestones signal a pivotal inflection point for pharmaceutical manufacturing, replacing a testing standard from decades ago that was not designed for modern therapies.
